OBJECTIVE: We performed a prospective cohort study in a homogeneous patient group with proven glioblastoma who received uniform therapy to determine the prognostic value and clinical correlates of [18F]fluorodeoxyglucose (FDG) PET at different stages of the disease. MATERIALS AND METHODS: Fifteen newly diagnosed patients with glioblastoma, aged 52 +/- 9 years and with Karnofsky performance score (KPS) of at least 50, were treated with surgical resection, chemotherapy (nimustine), and radiotherapy. They were followed prospectively for 2 years. Clinical data (e.g., tumor progression, performance status, and survival) were recorded and glucose metabolism was measured with PET and FDG before and during radiochemotherapy. RESULTS: Median survival of all patients was 13 months and four patients were alive 24 months after surgery. All tumors were hypermetabolic compared with normal white matter. A metabolic index was calculated as the ratio of maximum residual tumor metabolism to contralateral normal brain metabolism. It was of prognostic value for patient survival and tumor recurrence already in the first postoperative and all following PET studies and was correlated with the KPS. Reduction of contralateral brain metabolism was more closely related to prognosis than the tumor metabolism proper. CONCLUSION: These results underscore the prognostic relevance of metabolically active residual tumor tissue after surgical resection.

Adolescent↗

PubMedDate not supplied

Effect of prolonged administration of L-leucine-4-anti-pyrineamide dihydrochloride on certain organs and blood formation system in rat.

Newly synthesized L-leucine-4-antipyrineamide shows the biological effect of aminopyrine. In contrast, it does not cause any adverse effect on the growth of rat, and induces neither degeneration of the parenchymal organs nor agranulocytosis.

Agranulocytosis↗

PubMedDate not supplied

Pharmacological properties of a new derivative of piperidine: 4-acetyl-4-(3-chlorphenyl)-1-(3'-dimethylaminopropyl)-piperidine dihydrochloride, designated S1.

The effect of 4-acetyl-4-(3-chlorphenyl)-1-3'-dimethylaminopropyl)- -piperidine dihydrochloride on central nervous system, cardio-vasculary system and isolated organs of experimental animals was checked. Its analgesic and spasmalotytic properties were evaluated and the acute toxicity -- determined.

Analgesics↗

PubMedDate not supplied

Spasmoanalgesic properties of 4-propionyl-4--(3-chlorphenyl)-1-[3-(4-methylpiperazine)-propyl (-piperidine)] trihydrochloride.

The paper describes the biological activity and pharmacological properties, particularly the spasmolytic and analgesis effects, of newly synthesized 4-propionyl-4-3(3-chlorphenyl)-1-[3-(4-methyl-piperazine)-propyl]-piperidine trihydrochloride (denoted S10).

Analgesics↗

PubMedDate not supplied

Central and peripheral action of a new compound: 4-propionyl-4-(3-chlorphyenyl)-1-(3'-dimethylaminopropyl)-piperidine dihydrochloride (symbol S6).

Som pharmalogical properties of a new, biologically active combpound 4-propionyl-4-(3-chlorphenyl)-1-(3'-dimethylaminoprophy)-piperidine dihydrochloride (symbol S6) are presented.

Analgesics↗

PubMedDate not supplied

[Familial variant of the Y chromosome].

Explore the source record for details and available documents.

Adult↗

PubMedDate not supplied

[Studies of physico-chemical properties and erythrocyte metabolism in children with Down's syndrome].

Explore the source record for details and available documents.

Child↗

PubMedDate not supplied

[Free amino acids in erythrocytes of children with Down's syndrome].

Explore the source record for details and available documents.

Adolescent↗